Many Firsts As Celltrion/Pfizer’s Inflectra Becomes Second US Biosimilar
This article was originally published in PharmAsia News
Move over Zarxio, there's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion and Pfizer said they won't put it on the market until after June 29.
You may also be interested in...
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.